What is NextGen Jane?
NextGen Jane operates as a pioneering biotechnology entity dedicated to the longitudinal molecular study of menstruation. By transforming the way obstetric and gynecological health is monitored, the company empowers individuals to unlock actionable health data through non-invasive genomic analysis. Their core offering, a specialized collection kit, enables the systematic study of uterine biology, providing early indicators of health and disease that were previously inaccessible. This market position is critical, as it bridges the gap between consumer-facing health insights and clinical-grade diagnostic rigor, effectively creating a new category in women's health technology.
How much funding has NextGen Jane raised?
NextGen Jane has raised a total of $11.3M across 2 funding rounds:
Angel/Seed
$2.3M
Series A
$9M
Angel/Seed (2019): $2.3M with participation from Undisclosed
Series A (2019): $9M led by Material Impact, Liminal Ventures, Viking Global Investors, and Access Industries
Key Investors in NextGen Jane
Material Impact
Material Impact is a venture capital firm focused on building deep tech companies that leverage material science to drive innovation and solve complex global challenges.
Viking Global Investors
Viking Global Investors is a prominent investment firm specializing in research-intensive, long-term focused equity investments across diverse global industries.
Access Industries
Access Industries is a privately-held industrial conglomerate that makes strategic, long-term investments across sectors including biotechnology, media, and technology.
What's next for NextGen Jane?
With the recent influx of capital, NextGen Jane is poised to scale its operations and deepen its scientific research initiatives. The strategic focus will likely center on expanding the clinical validation of its molecular insights, which is essential for broader adoption within the medical community. As the company matures, the integration of its data platform into existing healthcare workflows will be a primary objective, potentially setting a new standard for personalized gynecological care. Investors are closely watching how the firm leverages this financing to navigate regulatory landscapes and establish partnerships with major healthcare providers, ultimately aiming to improve diagnostic accuracy and treatment outcomes for menstruators globally.
See full NextGen Jane company page
